scholarly article | Q13442814 |
P50 | author | Oğuzhan Alagöz | Q56654355 |
Ronald E Gangnon | Q56810665 | ||
Mehmet Ali Ergun | Q57334076 | ||
Donald H Berry | Q73566215 | ||
Clyde B Schechter | Q87050955 | ||
Diana Miglioretti | Q88168881 | ||
Amy Trentham-Dietz | Q88960210 | ||
Sylvia Plevritis | Q89453368 | ||
Eveline A M Heijnsdijk | Q89500454 | ||
Jeanne S Mandelblatt | Q90278289 | ||
Eric J Feuer | Q90907333 | ||
Brian L Sprague | Q91924355 | ||
Karla Kerlikowske | Q92299671 | ||
Nicolien T van Ravesteyn | Q98198718 | ||
Anna N. A. Tosteson | Q110143968 | ||
Aimee M Near | Q114374862 | ||
Natasha K Stout | Q114563134 | ||
Gary Chisholm | Q114563136 | ||
Jeroen J van den Broek | Q114563144 | ||
Kathleen A. Cronin | Q125588542 | ||
P2093 | author name string | Hui Huang | |
Harry J de Koning | |||
Xuelin Huang | |||
Sandra J Lee | |||
Yaojen Chang | |||
Amanda Hoeffken | |||
Diego Munoz | |||
Martin Krapcho | |||
P2860 | cites work | Screening for breast cancer with mammography | Q24202273 |
Genome-wide association studies identify four ER negative-specific breast cancer risk loci | Q24622610 | ||
Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis | Q24628928 | ||
Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods | Q26824867 | ||
The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model | Q27347267 | ||
Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement | Q28265041 | ||
Cancer screening in elderly patients: a framework for individualized decision making | Q33949364 | ||
Modification of breast cancer risk according to age and menopausal status: a combined analysis of five population-based case-control studies | Q33957073 | ||
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits | Q34159375 | ||
Prevalence of mammographically dense breasts in the United States | Q34354391 | ||
Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies | Q34386037 | ||
Quantifying the benefits and harms of screening mammography | Q34395037 | ||
Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial | Q34403715 | ||
Abolishing mammography screening programs? A view from the Swiss Medical Board. | Q34415457 | ||
Effect of screening and adjuvant therapy on mortality from breast cancer | Q34463105 | ||
A stochastic model for predicting the mortality of breast cancer | Q34573070 | ||
Long-term effects of mammography screening: updated overview of the Swedish randomised trials | Q34579899 | ||
Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality | Q34736052 | ||
Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine | Q34753553 | ||
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms | Q35013356 | ||
A reality check for overdiagnosis estimates associated with breast cancer screening | Q35102556 | ||
External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older | Q35171219 | ||
Public Opinions about Overdiagnosis: A National Community Survey | Q35629000 | ||
Identifying women with dense breasts at high risk for interval cancer: a cohort study | Q35646902 | ||
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials | Q35740423 | ||
Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures | Q35752042 | ||
Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality | Q36438347 | ||
Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk | Q36460671 | ||
Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
Performance benchmarks for screening mammography | Q36600843 | ||
A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends | Q36619879 | ||
Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates? | Q36659650 | ||
Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis | Q36770273 | ||
Genetic susceptibility to triple-negative breast cancer | Q36846498 | ||
Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy | Q36976948 | ||
Benign breast disease, mammographic breast density, and the risk of breast cancer | Q37021220 | ||
Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study | Q37054183 | ||
Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening | Q37070417 | ||
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness | Q37139381 | ||
Short-term outcomes of screening mammography using computer-aided detection: a population-based study of medicare enrollees | Q37169846 | ||
Impact of mammography screening interval on breast cancer diagnosis by menopausal status and BMI | Q37231420 | ||
Obesity, mammography use and accuracy, and advanced breast cancer risk | Q37324240 | ||
Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. | Q37548461 | ||
Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients | Q37601809 | ||
Cancer screening in the United States, 2012: A review of current American Cancer Society guidelines and current issues in cancer screening | Q37977324 | ||
The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies | Q38042894 | ||
European breast cancer service screening outcomes: a first balance sheet of the benefits and harms | Q38225849 | ||
Patients' expectations of the benefits and harms of treatments, screening, and tests: a systematic review | Q38296894 | ||
Breast-specific gamma imaging: correlations with mammographic and clinicopathologic characteristics of breast cancer | Q38437176 | ||
A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. | Q38465812 | ||
Diagnostic performance of digital versus film mammography for breast-cancer screening | Q39730356 | ||
Digital breast tomosynthesis and the challenges of implementing an emerging breast cancer screening technology into clinical practice | Q40154748 | ||
Breast cancer screening using tomosynthesis in combination with digital mammography | Q40209954 | ||
Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. | Q40261524 | ||
Breast-cancer screening--viewpoint of the IARC Working Group | Q41697220 | ||
Effect of age, breast density, and family history on the sensitivity of first screening mammography | Q45149178 | ||
The value of modern mammography screening in the control of breast cancer: understanding the underpinnings of the current debates. | Q50111734 | ||
The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. | Q50192553 | ||
Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. | Q51914599 | ||
Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. | Q51931359 | ||
Retrospective cost-effectiveness analysis of screening mammography. | Q53241570 | ||
Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. | Q53474457 | ||
Breast-specific gamma imaging for the detection of breast cancer in dense versus nondense breasts. | Q53635144 | ||
Mammographic Density and the Risk and Detection of Breast Cancer | Q59545042 | ||
Chapter 9: The MISCAN-Fadia Continuous Tumor Growth Model for Breast Cancer | Q61881608 | ||
The impact of a breast cancer screening programme on quality-adjusted life-years | Q68009566 | ||
The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up | Q74174362 | ||
Changing patterns in breast cancer incidence trends | Q79220373 | ||
The Wisconsin Breast Cancer Epidemiology Simulation Model | Q79220380 | ||
Prospective breast cancer risk prediction model for women undergoing screening mammography | Q80216670 | ||
The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy | Q86069475 | ||
The harms and benefits of modern screening mammography | Q88098170 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | collaboration | Q1145523 |
breast cancer screening | Q17011492 | ||
P304 | page(s) | 215-225 | |
P577 | publication date | 2016-01-12 | |
P1433 | published in | Annals of Internal Medicine | Q564416 |
P1476 | title | Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies | |
P478 | volume | 164 |
Q38669521 | A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality. |
Q92199197 | A systematic review and quality assessment of individualised breast cancer risk prediction models |
Q60175951 | Breast Cancer Incidence by Stage Before and After Change in Screening Guidelines |
Q30238753 | Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. |
Q64461485 | Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling |
Q92528444 | Comparative Validation of Breast Cancer Risk Prediction Models and Projections for Future Risk Stratification |
Q47304201 | Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening. |
Q51738443 | Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49. |
Q51738440 | Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology. |
Q46212925 | Comparison of recommendations for screening mammography using CISNET models |
Q64461488 | Contribution of Breast Cancer to Overall Mortality for US Women |
Q47198620 | Cost Effectiveness of Gene Expression Profile Testing in Community Practice. |
Q88960776 | Cost-Effectiveness of Breast Cancer Screening in Turkey, a Developing Country: Results from Bahçeşehir Mammography Screening Project |
Q47218784 | Distinguishing between CISNET model results versus CISNET models |
Q47336549 | Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study |
Q52350449 | Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment. |
Q91895021 | Estimating the cost-effectiveness of salt reformulation and increasing access to leisure centres in England, with PRIMEtime CE model validation using the AdViSHE tool |
Q48104203 | Estimating the frequency of indolent breast cancer in screening trials |
Q33859917 | Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force |
Q49571883 | Factors associated with false positive results on screening mammography in a population of predominantly Hispanic women. |
Q64109359 | Factors associated with false-positive mammography at first screen in an Asian population |
Q33763563 | Imaging Surveillance After Primary Breast Cancer Treatment |
Q88098279 | Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models |
Q64935691 | Is risk-stratified breast cancer screening economically efficient in Germany? |
Q56334456 | Linkage of the ACR National Mammography Database to the Network of State Cancer Registries: Proof of Concept Evaluation by the ACR National Mammography Database Committee |
Q88098258 | Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches |
Q48369270 | Opportunity cost of annual screening mammography. |
Q89622252 | Optimizing selection of candidates for lung cancer screening: role of comorbidity, frailty and life expectancy |
Q37720423 | Overdiagnosis of breast cancer in population screening: does it make breast screening worthless? |
Q91894841 | PRIMEtime CE: a multistate life table model for estimating the cost-effectiveness of interventions affecting diet and physical activity |
Q37567500 | Persuasive Interventions for Controversial Cancer Screening Recommendations: Testing a Novel Approach to Help Patients Make Evidence-Based Decisions. |
Q49920221 | Physicians discuss ramifications of studies pointing to breast cancer overdiagnosis: New research under way attempts to better define who should be screened and treated. |
Q30251601 | Population-based screening for cancer: hope and hype. |
Q44876590 | Probabilistic sensitivity analysis on Markov models with uncertain transition probabilities: an application in evaluating treatment decisions for type 2 diabetes. |
Q36908218 | Progress Toward Consensus on Breast Cancer Screening Guidelines and Reducing Screening Harms |
Q42370817 | Progress Toward Consensus on Breast Cancer Screening Guidelines and Reducing Screening Harms--Reply |
Q48348309 | Reply to Distinguishing between CISNET model results versus CISNET models. |
Q46841562 | Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors |
Q39347821 | Risk-based Breast Cancer Screening: Implications of Breast Density |
Q90590047 | Screening mammography outcomes: risk of breast cancer and mortality by comorbidity score and age |
Q49589211 | Short- and Long-Term (10-year) Results of an Organized, Population-Based Breast Cancer Screening Program: Comparative, Observational Study from Hungary. |
Q52648599 | Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia. |
Q88541401 | Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer |
Q52648603 | Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model. |
Q37444608 | Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes |
Q47130981 | The Complexity of Achieving the Promise of Precision Breast Cancer Screening. |
Q52648600 | The Dana-Farber CISNET Model for Breast Cancer Screening Strategies: An Update. |
Q60175954 | Trends in breast cancer mortality by stage at diagnosis among young women in the United States |
Q90585615 | Use and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance |
Q51365548 | Using Collaborative Simulation Modeling to Develop a Web-Based Tool to Support Policy-Level Decision Making About Breast Cancer Screening Initiation Age. |
Q50281308 | Validating a breast cancer score in Spanish women. The MCC-Spain study. |
Q55315231 | Women's decision-making regarding risk-stratified breast cancer screening and prevention from the perspective of international healthcare professionals. |
Search more.